Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's what I used to think. Embryonic stems cells had too much negativity surrounding them, so companies rushed to develop Adult Stem Cells. Adult stem cells work, but are old and do not pack a punch like Placental cells do. Placental cells bridge the mother/baby gap. They are true Allogeneic.
People are slow learners. Pluristem has the best cells and they know it. FDA is right... soon the rest of the world will find out!
Placental stem cells can regenerate heart after attack: Study
"They almost seem like a super-charged population of stem cells, in that they can target the site of an injury and travel directly to the injury through the circulatory system and are able to avoid rejection by the host immune system,"
They showed that the placental stem cells migrated to the mother's heart and directly to the site of the heart injury. The stem cells then programmed themselves as beating heart cells to help the repair process.
Time for Investors to Bail on Etsy Inc?
Etsy stock has steadily declined since the company debuted earlier this year. However, the sell-off could be overblown as the company looks to unlock new revenue in manufacturing.
Etsy (NASDAQ:ETSY) made its stock market debut earlier this year to great fanfare. The stock finished its first day as a publicly traded company up 88% to $30 per share. Unfortunately, those gains were short-lived for the crafts marketplace. The stock has since plummeted more than 70% to where it trades today, below $9 per share. This downfall has earned it the title of worst initial public offering of 2015 (so far). Ouch.
If you are still an Etsy shareholder, there is a good chance you're ready to run for the exits now that e-commerce giant Amazon (NASDAQ:AMZN) has released its so-called Etsy killer. However, there may be more upside ahead for the company, despite its double-digit sell-off this year.
Does Wall Street misunderstand Etsy?
It's easy to dismiss Etsy as a niche player in a massive ocean of online retailers. However, Etsy is a real business that has grown from $300 million in commerce in 2011 to around $1.9 billion last year. The online marketplace reported gross merchandise sales of $569 million during its fiscal 2015 third quarter, which was an increase of nearly 22% over the same period last year. Additionally, revenue climbed more than 37% year-over-year to $65 million for the period. This was primarily driven by a 66% spike in revenue from seller services as more sellers utilized Etsy's promoted listings option.
While those results seem encouraging, Wall Street isn't happy about mounting costs as Etsy aims to grow its business both at home and abroad. During the third quarter, for example, operating expenses ballooned 32% year-over-year to $43 million.
While mounting costs can be worrisome, investors should remember that Etsy is still tiny compared to online rivals such as Amazon and eBay (NASDAQ:EBAY). Etsy therefore needs to invest ample cash in marketing and infrastructure in order to grow its online presence in this increasingly competitive space. Importantly, Etsy's operating expenses as a percentage of revenue actually decreased slightly in the third quarter as revenue growth outpaced expenses.
Signs of an overblown sell-off
With the stock down over 20% in the past month alone, you would think Etsy was bleeding sellers or struggling to attract new shoppers. That's not the case. In fact, in the latest quarter, Etsy grew its seller base by nearly 20%, while active buyers (shoppers who have made at least one purchase with Etsy in the past year) increased 25% year-over-year.
There are also signs that Etsy has ambitions to grow beyond its niche roots. The company recently launched Etsy Manufacturing, which aims to scale Etsy's business by connecting sellers with manufacturers the company has already vetted.
By acting as the middleman in these designer-manufacturer relationships, Etsy is digging out another potentially lucrative revenue stream. Etsy plans to begin charging both designers and manufacturers transaction fees in 2016. The company's manufacturing marketplace, as it is being called, is currently in Beta. However, the concept could lead to future earnings growth for Etsy -- thereby offering another reason the double-digit sell-off may be overblown here, particularly for long-term investors.
Living in an Amazon-driven world
On top of increased spending costs, analysts also worry about Amazon being a so-called Etsy killer. Last month, Amazon launched Handmade, a direct competitor to both eBay and Etsy that offers handcrafted items from artisans around the world. Given Amazon's 285 million active users, it makes sense that Etsy and eBay should worry.
Martha Stewart has pulled her American Made store from eBay and instead opened up shop on Amazon's Handmade marketplace after a nearly two-year relationship with eBay. The do-it-yourself mogul said she made the move because of Amazon's outsized scale and customer base. Amazon's Handmade site now contains over 200,000 items -- a figure that continues to grow.
Nevertheless, Etsy and eBay both remain confident in their respective businesses. eBay sells upwards of a half a billion dollars annually in handmade merchandise, according to the company's VP for merchandising. Meanwhile, Etsy's chief executive recently told shareholders that based on conversations with the company's sellers, "we have no reason to believe that any competitors are having an impact on our seller business right now."
There is tremendous demand for handcrafted products. Ultimately, I believe this strong demand means there is plenty of room in the market for multiple players. Moreover, Etsy remains competitive with Amazon Handmade in regards to both pricing and product selections. For example, Etsy currently boasts around 36 million items on its marketplace and 1.5 million active sellers. That compares to around 200,000 products on Amazon Handmade from around 10,000 sellers. Etsy also offers sellers lower transaction fees versus Amazon, which could compel more sellers to stick with Etsy or, at the very least, to sell on both sites.
Takeaway for investors
This is far from the end for Etsy, and with the stock trading near its all-time low today, there is a clear opportunity for investors to own a promising turnaround story. For this reason, I don't believe investors should bail on Etsy but should instead stick around for what could be a very rewarding comeback play.
SEC Charges Two College Professors in Naked Short Selling Scheme
Data Analysis by SEC Staff Breaks Case
Colak and Kostov used multiple brokerage accounts to disguise the spurious nature of the sham transactions, moving a short position from one brokerage firm to another every few days in order to spread the failures to deliver across multiple firms in an effort to avoid detection. SEC investigators uncovered the complicated scheme while looking into unusual trading in one of the companies whose options were being traded by Colak and Kostov. An SEC examiner separately noted Kostov’s large volume options trading in a different company. By cross referencing their findings and crunching blue sheet data, it became clear that Colak and Kostov were likely trading with one another. SEC investigators pieced together the complex trading strategy – which involved literally thousands of trades – by tracing one of the trading sequences from start to finish.
The advancement of human pluripotent stem cell-derived
therapies into the clinic.
Link
FOIA Logs
----------------------
Request ID: 15-02555-FOIA
Requester Name: Rivero, Damian
Requester Category: Commercial Organization
Request Description: Ocata Therapeutics Inc
Requested Date: 3/23/15
Closed Date: 4/3/15
Final Disposition: Denied in full
Current status of pluripotent stem cells: moving the first therapies to the clinic
Erin A. Kimbrel & Robert Lanza
Published online 22 September 2015
The figure shows the numerous cell types that can be derived from pluripotent stem cells, which can be used to treat a range of diseases. These cell types include: various neurons or neuronal progenitors for the treatment of neurodegenerative disorders and injuries (part a); retinal cell types for the treatment of ocular diseases (part b); alveolar cells for the treatment of lung disease and injury (part c); insulin-producing (pancreatic ß-cells) for the treatment of diabetes (part d); intestinal cells for the treatment of Crohn disease and irritable bowel disease (part e); various blood cell types for the treatment of haematological disorders (part f); hepatocytes for the treatment of liver disease and toxicity screening (part g); cardiac progenitors and cardiac muscle cells for the treatment of heart disease (part h); and skin and/or hair follicles for the treatment of wounds, ulcers and hair loss (part i).
OCAT Equity Ownership
# of Institution Owners: 51
# of Fund Owners: 44
% Owned by Institutions: 4.45
% Owned by Funds: 5.66
% Owned by Insiders: 0.33
morningstar.com
Five Companies Developing Induced Pluripotent Stem Cell Therapies
2) Ocata Therapeutics
Ocata Therapeutics, previously Advanced Cell Technology (ACT), is a biotechnology company that specializes in the development of cellular therapies, using both adult and human embryonic stem cells to develop patient-specific therapies. The company’s main laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California.
When a number of private companies began to explore the possibility of using artificially re-manufactured iPSCs for therapeutic purposes, one such company that was ready to capitalize on the breakthrough technology was Ocata Therapeutics, at the time called Advanced Cell Technology (ACT). In 2010, the company announced that it had discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced. [16]
As a result, the company has since shifted its induced pluripotent stem cell approach to producing iPS cell-derived human platelets, as one of the benefits of a platelet-based product is that platelets do not contain nuclei, and therefore, cannot divide or carry genetic information. While nothing is completely safe, iPS cell-derived platelets are likely to be much safer than other iPSC therapies, in which uncontrolled proliferation is a major concern. However, while the company’s “Induced Pluripotent Stem Cell-Derived Human Platelet Program” received a great deal of media coverage in late 2012, including being awarded the December 2012 honor of being named one of the “10 Ideas that Will Shape the Year” by New Scientist Magazine,[17] the company did not succeed in moving the concept through to clinical testing in 2013.
Nonetheless, on May 1, 2013, the CEO and Chairman of Ocata Therapeutics, Gary Rabin, wrote in a written interview for the Knoepfler Lab Stem Cell Blog that, “Our IP position includes claims around inducing pluripotency using Oct-4, as well as zero footprint reprogramming using vectorless technology. We see our platelets program as only the beginning of our iPS cell-based program; we are planning to target other indications as well.”[18]
Ocata Therapeutics Becomes Oversold (OCAT)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Ocata Therapeutics Inc (OCAT) entered into oversold territory, hitting an RSI reading of 27.2, after changing hands as low as $4.95 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 35.8. A bullish investor could look at OCAT's 27.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of OCAT shares:
The Street
This five kinds of disease that has a new therapy, and then let them furious!
Some types of disease will gradually deteriorate over time, becoming more and more destructive. Now, the scientific community has the ability to dial back some of the ills of the clock.
From "Technology Life | Popular Science"
Blindness:
Blindness stem cell therapy to restore vision
After the older man had macular degeneration, it will gradually lose their eyesight. Many patients did not completely blind, but the object of their vision becomes blurred, color fade, and eventually even not recognize faces. Last fall, Ocata Therapeutics company reported a deterioration of eyesight can save human embryonic stem cell therapy. When macular degeneration, called "retinal pigment epithelium" thin layer of tissue degradation. Because this layer is responsible for the organization of the cone to the eye, rod cells deliver nutrients and oxygen, when it stalled followed those of visible light receptor was a calamity. Ocata's coping strategy is to induce embryonic stem cells differentiate into retinal pigment epithelium cells, then inject these cells in the eye. These cells into the eye in the end play what role, it is unclear - they may make the original dying cone, rod cells rebirth, may also have a new cone, rod cells. But no matter how the principles, we really began to see the light of the patient.
Two clinical studies published last year show that the therapy does work. 18 treated 10 patients had improved sensory acuity, another seven people to stop the decline of vision. A few even made a very significant recovery: A 75-year-old farmer, had completely blind in one eye, and now he even started riding the. Although stem cell therapy approved by the US Food and Drug Administration (FDA) of the need to wait a few years, but one day, the therapy may become as popular like cataract surgery.
Link to poorly translated article.
LinkedIn › eddyanglade
Greater Boston Area - ?Chief Medical Officer | Clinical/Regulatory Strategy and Implementation
Mobile-friendly - Ocata Therapeutics, Inc. Previous ..
Preparation of grant proposal for submission to Juvenile Diabetes Foundation
Japan Announces Early Approval System for Regenerative ...
Apr 14, 2015
Japan’s drug authority will grant conditional approval to human embryonic and somatic stem cell therapies based on limited clinical data, under a new approval pathway meant to speed patient access to innovative products.
New regulations accelerating the approval of regenerative therapeutics in Japan took effect Nov. 25, 2014, propelling that nation onto the radar screens of life sciences companies around the world. The chief benefit of these new rules is that they enable companies to receive conditional marketing approval and generate revenue from regenerative products while trials are being conducted.
"A lot of people here (in the U.S.) don’t know about it,” says Gil Van Bokkelen, Ph.D., CEO and chairman of Athersys and ex officio chair of the Alliance for Regenerative Medicine. “As more visibility and tangible progress is generated, I think it will create a lot of additional interest and excitement.”
----------------------------------------------
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
Japan's Bold Initiative in Regenerative Medicine
Last spring, the MHLW and PMDA (the equivalent of the U.S. FDA in Japan) announced the concept of a new framework designed to dramatically accelerate the development of new regenerative medicine therapies that could help address areas of significant unmet medical need.
Japan’s new policy requires an early stage clinical trial (call it a Phase I or small Phase II) at the minimum to confirm safety of the therapy and provide some plausible evidence of efficacy. Rather than requiring that the therapy then be evaluated in subsequent trials before making it available to patients, Japan’s new law will allow for a “conditional approval” enabling the product to be brought to market, and for the product to obtain reimbursement in an accelerated manner.
In a recent keynote speech at the World Economic Forum in Davos, Switzerland, Prime Minister Shinzo Abe reiterated Japan’s national commitment to leadership in regenerative medicine, saying, “We will make it possible to generate cells (i.e. cell based medicines) at private sector factories.”
What does this mean? Anything?
Originator Advanced Cell Technology
Developer CHA Bio & Diostech; Ocata Therapeutics
Class Eye disorder therapies; Stem cell therapies
Mechanism of Action Cell replacements
Orphan Drug Status Yes - Stargardt disease
Available For Licensing Yes - Age-related macular degeneration; Stargardt disease
Highest Development Phases
Phase I/II Age-related macular degeneration; Degenerative myopia; Stargardt disease
Most Recent Events
29 Apr 2015 TMC Pharma Services initiates a phase I/II extension trial in Stargardt Disease 1 in United Kingdom (UKCRN 18822) before April 2015
------------------------------------
hemangio derived mesenchymal cells - Ocata Therapeutics
Available For Licensing Yes
Most Recent Events
16 Mar 2015 Research programme: hemangio derived mesenchymal cells - Ocata Therapeutics is available for licensing as of 16 Mar 2015. https://www.ocata.com/
Stem Cell Reports, Volume 3
Supplemental Information
Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells
Plenary Paper
PLATELETS AND THROMBOPOIESIS
Platelet bioreactor-on-a-chip
Strong ARMing regenerative medicine; bold thoughts on a bright future
Paul Wotton, the President and CEO of Ocata Therapeutics (formerly called ACT) echoed those sentiments:
“We are pioneering things here and it’s the pioneers who often end up with arrows in their back, so you really have to spend a lot of time working with the FDA and other regulatory bodies to make sure you are having all the right conversations ahead of time.”
Discover's 100 top stories of 2014 is jam-packed with the best in science from the past year. From space exploration to medicine, technology, paleontology and environment, we've got every field covered.
#12 Stem Cells Make Insulin, Restore Retinas
#26 Platelet Production, Pumped Up
All 32 million shares have been diluted and are in the hands of loyal retail investors who have been holding for years and will continue to hold.
The 10 million share offering has a 180 day lockup period. So none of those shares will be hitting the market until the Summer 2015. By that time OCAT will have reached several milestones.
When the lockup period ends after several milestones have been reached, I doubt these institutions will be selling. So this dilution talk is nonsense.
Some of these large investors wanted to see some updated numbers from OCAT and have the company focus adjusted, that's what this new 8k is about. Pleasing the large investors and getting the price OCAT wants.
Well... according to NASDAQ, OCAT is NASDAQ listed! Hahaha...
Exchange: NASDAQ
My philosophy:
Stock message boards are like Soap Operas. Fun to watch and pick your favorite characters and villains, but don't get too involved in the fictitious stories.
I'm locked out on etrade. Tried to buy a couples times today just to see if I could. Keeps giving me an error.
Woohoo!! Same with my etrade account!
Symbol: OCAT
Exchange: Nasdaq SmallCap Market
Share Price: $6.21
Shares Offered: 10,000,000
Offer Amount: $62,100,000.00
Read more: http://www.nasdaq.com/markets/spos/company/ocata-therapeutics-inc-86431-76711#ixzz3KybUiuAV
So is this official then?
2014 Q4 • Up-listing of company stock to Nasdaq
from the
Corporate Presentation
November 2014
An Organ Regeneration Platform for
Industrial Production of Hollow Neo-Organs
Published: November 26, 2014
Tengion’s organ regeneration platform
The new logo has a Santa fe, NM feel about it with the colors and typeface. Very medicine man.
STEM: StemCells Inc. Faces Tough Times Ahead
"It would have been great news to slow the rate of AMD progression by 70% if one of their competitors, Advanced Cell Technology (OTCQB:ACTC), had not completely halted the disease in patients enrolled in their Phase I trial. Many of ACT's patients even experienced persistent gains in visual acuity. In my previous article, I postulated that Phase I results in stem cell trials were likely to persist throughout the ensuing trial phases. That won't be good enough for STEM. They're going to need to show better efficacy to keep up with the competition."
Tom Franey, contributor
Author’s reply » The pipeline is great, but people have a problem believing large numbers. If I included other applications in the valuation it would be incomprehensible for most.
This is interesting...
-------------------------------
Army Medical Research and Materiel Command, meanwhile, is studying wound-healing technologies. One project in the works aims to develop a synthetic blood substitute that could be injected into a soldier’s bloodstream, said Col. Todd Rasmussen, the command’s director of the combat casualty care research program. The medicine mimics the properties of hemoglobin — the main component of a red blood cell — and would reduce the need for medics to delve into their precious supply of blood.
“These are things that are more in the test tubes and rats and mice at this point,” he said. “We are working to make sure the synthetic hemoglobins are compatible with living tissue.”
New Biological Technologies Will Grant Troops Super Powers - November 2014
--------------------------------
And then the fact that the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells study was partially supported by NIH grants.
Robert Lanza ?@robertlanza 20m20 minutes ago
CELL PRESS: Stem Cell Reports "Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells"
Can the upcoming Phase 2 trials use embryonic stem cells and induced pluripotent stem cells to find out what works best?
"We now have two ways and we're not sure which of the two methods is likely to work best," Lanza says.
First Embryonic Stem Cells Cloned From A Man's Skin
With the current media blitz, ACT really needs to emphasize that they have No Embryo Destruction cells. Seriously, they need to say that every chance they get.
Stem cells, blindness and why the media loves miracle cures
ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
Phase 1/2 Clinical Trials of RPE Cells for the Treatment of Dry Age-Related Macular Degeneration and Stargardt’s Macular Degeneration Show Positive Long Term Safety Results and Signs of Visual Improvement
ACT to Host a Conference Call on Wednesday, October 15, 2014 at 4:30 PM Eastern Time. Interested Parties may access the call live by dialing (888) 264-3177 and using Conference ID 18428590. A Webcast is available at http://engage.vevent.com/rt/act~advancedcelltechnology101514
MARLBOROUGH, Mass.-- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative ophthalmology, announced today that Phase 1/2 clinical data published online in The Lancet demonstrate positive long-term safety results using ACT’s proprietary Retinal Pigment Epithelium (RPE) cells for the treatment of Stargardt’s macular degeneration (SMD) and dry age-related macular degeneration (AMD). The publication features data from 18 U.S.-based patients with at least six months of post-transplant follow-up.
“These study results represent an important milestone and strengthen our leadership position in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “We would like to thank the patients for their willingness to participate in these studies. Our findings underscore the potential to repair or replace tissues damaged from diseases. We plan to initiate comprehensive Phase 2 clinical trials for the treatment of both AMD and SMD, two disease states where there is currently no effective treatment.”
These two studies provide the first evidence of the mid- to long-term safety, survival, and potential biologic activity of pluripotent stem cell progeny into humans with any disease. In addition to showing no adverse safety issues related to the transplanted tissue, anatomic evidence confirmed successful engraftment of the RPE cells, which included increased pigmentation at the level of the RPE layer after transplantation in 13 of 18 patients.
Robert Lanza, M.D., Chief Scientific Officer of ACT and co-senior author of the paper, commented, “Diseases affecting the eye are attractive first-in-man applications for this type of investigational therapy due to the immune-privileged nature of the eye. Despite the degenerative nature of these diseases, the vision of 10 of 18 patients showed measurable improvement at the six month follow up, after transplantation of the RPE cells. Furthermore, the cells have been well tolerated for a median period of 22 months with two of the patients treated more than three years ago. We are pleased that there have been no serious safety issues attributable to the cells observed in any of the patients.”
Vision was measured using the widely accepted standard for visual acuity testing, the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity exam.
Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA’s Jules Stein Eye Institute, principal investigator and lead author of the publication said “The data published in The Lancet support the potential safety and biological activity of stem cell-derived retinal tissue. Once again, surgical access to the subretinal space has proven safe. However, for the first time in humans, terminally differentiated stem cell progeny seem to survive, and do so without safety signals. Combined with the functional signals observed, these data suggest that this regenerative strategy should move forward. This is a hopeful and exciting time for ophthalmology and regenerative medicine.”
About the Trials
The SMD and dry AMD trials are prospective, open-label studies designed to evaluate the safety and tolerability of human embryonic stem cell (hESC)-derived RPE cells following sub-retinal transplantation into patients at 12 months, the studies’ primary endpoint. Three dose cohorts were treated for each condition in an ascending dosage format (50,000 cells, 100,000 cells, and 150,000 cells). Both the SMD and dry AMD patients had subretinal transplantation of fully-differentiated RPE cells derived from hESCs. In addition to the two clinical trials in the U.S., ACT is carrying out a Phase 1/2 clinical trial of hESC-derived stem cells for the treatment of SMD in the United Kingdom.
About Age-related Macular Degeneration
Age-related macular degeneration is the leading cause of vision loss in people over the age of 50, with late stage AMD affecting about 30 million people worldwide. Dry AMD, accounts for 90 percent of all AMD and occurs when light-sensitive cells in the macula, located in the center of the retina, slowly break down, causing vision loss. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD. Including the earlier stages of disease, the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people. Loss of vision is an inevitable aspect of SMD, with more than half of patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, there are no treatments currently approved to prevent or slow the vision loss associated with SMD.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., (ACT) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technology. ACT’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt’s macular degeneration and myopic macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. ACT’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.advancedcell.com
Couldn't ACTC's blood program create large amounts of this doctors blood with the Ebola antibodies in it?
Texas nurse fighting Ebola receives blood transfusion from survivor Dr Kent Brantly - who also matched blood types with two others struck by the deadly virus in the U.S.
Wow - what a drop. Every couple days I check this and think NOW is the time to buy. Now I just don't know.
"jmymanning: $ACTCD new SA article on expected patient results out tomorrow morning after 24 hr SA PRO embargo.
about 2 hours ago from Twitter Web Client"